Paper41520156
Actionable genomic landscape of biliary tract cancer in the Indian population.
Limaye S and 24 others. Oncologist, 2026. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Actionable genomic landscape of biliary tract cancer in the Indian population. Papers, record 41520156. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41520156
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Genomics | Major topic |
| Biliary Tract Neoplasms | Major topic |
| Bile Duct Neoplasms | Major topic |
| Humans | |
| India | |
| Male | |
| Female | |
| Mutation | |
| Middle Aged | |
| DNA Copy Number Variations | |
| Aged | |
| Retrospective Studies |
Source PubMed
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34730772 | Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma. | JAMA Surg | 2022 | https://conductscience.org/library/papers/34730772 | PubMed |
| 2 | 32416072 | Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/32416072 | PubMed |
| 3 | 31015767 | Biliary tract cancers: current knowledge, clinical candidates and future challenges. | Cancer Manag Res | 2019 | https://conductscience.org/library/papers/31015767 | PubMed |
| 4 | 37386793 | Contribution of PGAP3 co-amplified and co-overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer. | J Cell Mol Med | 2023 | https://conductscience.org/library/papers/37386793 | PubMed |
| 5 | 38319896 | Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. | NEJM Evid | 2022 | https://conductscience.org/library/papers/38319896 | PubMed |
| 6 | 34554208 | Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. | JAMA Oncol | 2021 | https://conductscience.org/library/papers/34554208 | PubMed |
| 7 | 37444422 | Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37444422 | PubMed |
| 8 | 37709624 | Epidemiology of cholangiocarcinoma. | Eur J Surg Oncol | 2025 | https://conductscience.org/library/papers/37709624 | PubMed |
| 9 | 33744718 | STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications. | Eur J Cancer | 2021 | https://conductscience.org/library/papers/33744718 | PubMed |
| 10 | 38626513 | Unresectable biliary tract cancer: Current and future systemic therapy. | Eur J Cancer | 2024 | https://conductscience.org/library/papers/38626513 | PubMed |
| 11 | 24508317 | Molecular characterization of gallbladder cancer using somatic mutation profiling. | Hum Pathol | 2014 | https://conductscience.org/library/papers/24508317 | PubMed |
| 12 | 35155243 | Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer. | Front Oncol | 2022 | https://conductscience.org/library/papers/35155243 | PubMed |
| 13 | 40148974 | Epidemiology of gall bladder cancer and its prevalence worldwide: a meta-analysis. | Orphanet J Rare Dis | 2025 | https://conductscience.org/library/papers/40148974 | PubMed |
| 14 | 35814257 | LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35814257 | PubMed |
| 15 | 32373065 | Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism. | Front Endocrinol (Lausanne) | 2020 | https://conductscience.org/library/papers/32373065 | PubMed |
| 16 | 28008299 | KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers. | Jpn Clin Med | 2016 | https://conductscience.org/library/papers/28008299 | PubMed |
| 17 | 37017301 | FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice. | Pathologica | 2023 | https://conductscience.org/library/papers/37017301 | PubMed |
| 18 | 36372281 | Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Ann Oncol | 2023 | https://conductscience.org/library/papers/36372281 | PubMed |
| 19 | 35317947 | Meta-analysis on prognostic value of KRAS mutation in resected mass-forming cholangiocarcinoma. | Eur J Surg Oncol | 2022 | https://conductscience.org/library/papers/35317947 | PubMed |
| 20 | 35871236 | Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing. | Br J Cancer | 2022 | https://conductscience.org/library/papers/35871236 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42528623 | mTOR signaling in cholangiocarcinoma: mechanistic insights and therapeutic opportunities. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42528623 | PubMed |
| 42033611 | Genomic landscape and clinicopathological predictors of survival in gallbladder cancer. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/42033611 | PubMed |
| 42010540 | Genomic landscape of cholangiocarcinoma in India: ethnic variants and implications for targeted therapy. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42010540 | PubMed |
Genes14
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41520156
GET https://conductscience.org/api/papers/v1/41520156/authors?page=2